<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381847</url>
  </required_header>
  <id_info>
    <org_study_id>NDTHNanjingUMS</org_study_id>
    <nct_id>NCT02381847</nct_id>
  </id_info>
  <brief_title>Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients</brief_title>
  <official_title>Prospective Phase III Trial Using Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Including Adenocarcinoma of the Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histological proven advanced gastric cancer (including cancer of the&#xD;
      esophagogastric junction (AEG) without evidence of distant metastases, who fulfill the&#xD;
      inclusion and exclusion criteria, can be recruited in this study. There are two treatment&#xD;
      groups (A and B). The D2 radical gastrectomy will be applied in both groups. Patients&#xD;
      randomized into group B will be treated with an intraperitoneal (in the abdominal cavity)&#xD;
      chemoperfusion with cisplatin(75mg/m2 max 150mg/m2 max 5L ). Patients randomized into group A&#xD;
      will not accept intraperitoneal chemoperfusion. Patients in both groups receive 6 cycles of&#xD;
      postoperative chemotherapy (SOX or XELOX) within 4-12 weeks after the surgical procedure and&#xD;
      are followed up for 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the trial is to compare the treatment of patients with advanced gastric&#xD;
      cancer without evidence of distant metastases treated with D2 radical gastrectomy and&#xD;
      intraperitoneal chemoperfusion (HIPEC) and postoperative chemotherapy (Group B) and patients&#xD;
      treated with D2 radical gastrectomy alone and postoperative chemotherapy (Group A).&#xD;
&#xD;
      The hypothesis of the trial is that D2 radical gastrectomy with intraperitoneal&#xD;
      chemoperfusion (Group B) is superior to D2 radical gastrectomy (Group A) in terms of overall&#xD;
      survival.&#xD;
&#xD;
      The trial is designed as a prospective, randomized, open, multicenter and parallel group&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>overall survival [ Time Frame: Death or 2 years ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progress</measure>
    <time_frame>24 months</time_frame>
    <description>follow up every 3 months till 24 months end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to distant metastasis</measure>
    <time_frame>24 months</time_frame>
    <description>time to other distant metastases follow up every 3 months till 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malignant Neoplasm of Stomach</condition>
  <arm_group>
    <arm_group_label>without HIPEC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.&#xD;
Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intraperitoneal chemoperfusion</intervention_name>
    <description>HIPEC with cisplatin at the time of D2 radical surgery</description>
    <arm_group_label>with HIPEC</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proved diagnosis of peritoneal metastasized gastric cancer including&#xD;
             carcinoma of the AEG.&#xD;
&#xD;
          -  No evidence of distant metastases&#xD;
&#xD;
          -  preoperative examination (CT/MRI) demonstrated resectable gastricc cancer with T3-T4&#xD;
             stage&#xD;
&#xD;
          -  Written informed consent is obtained prior to commencement of trial treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous chemotherapy or radiotherapy, and any investigational treatment for&#xD;
             gastric cancer&#xD;
&#xD;
          -  Active systemic infections&#xD;
&#xD;
          -  Patients with known interstitial lung disease with New York Heart Association&#xD;
             classification &gt; 2&#xD;
&#xD;
          -  Serious cardiac dysrhythmia or condition, New York Heart Association classification of&#xD;
             III or IV, congestive cardiac failure&#xD;
&#xD;
          -  cardiac arrhythmia&#xD;
&#xD;
          -  Inadequate renal function at the beginning of the trial, defined as GFR less than &lt;60&#xD;
             ml/min&#xD;
&#xD;
          -  Inadequate liver function at the beginning of the trial, defined as Bilirubin &gt;1.5&#xD;
             times ULN&#xD;
&#xD;
          -  Inadequate bone marrow function at the beginning of the trial, defined as platelet&#xD;
             count less than &lt;150 GPT/L or neutrophil granulocyte count less than &lt;1.5 GPT/&#xD;
&#xD;
          -  Active vaccination within 6 weeks prior to randomisation&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Missing of capacity to contract&#xD;
&#xD;
          -  contraindication to the drugs which are used in the trial&#xD;
&#xD;
          -  Participation in another therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenxian Guan</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Health Ministry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Wang</last_name>
    <phone>86-13815890469</phone>
    <email>wangmeng001@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenxian Guan</last_name>
    <phone>86-83106666-60931</phone>
    <email>guan_wx@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meng Wang</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Wang</last_name>
      <phone>86-13815890469</phone>
      <email>wangmeng001@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Wenxian Guan</last_name>
      <phone>86-25-83106666</phone>
      <email>guan_wx@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wenxian Guan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Baorui Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 28, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Wenxian Guan</investigator_full_name>
    <investigator_title>Dean of General Surgery Department, Nanjing Drum Tower Hospital</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>intraperitoneal chemoperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

